Description

Faslodex Solution for Injections 250 mg/5 ml Filled Syringe 5 ml №2

Ingredients:

Faslodex contains the active ingredient fulvestrant, which is a selective estrogen receptor degrader (SERD). Each 5 ml pre-filled syringe contains 250 mg of fulvestrant.

Dosage:

The recommended dose of Faslodex is 500 mg (2 injections of 250 mg) administered intramuscularly into the buttocks, with one injection given on each side, on days 1, 15, 29, and once monthly thereafter.

Indications:

Faslodex is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Contraindications:

Faslodex is contraindicated in individuals with known hypersensitivity to fulvestrant or any component of the formulation.

Directions:

Administer Faslodex under the supervision of a healthcare provider. The injection should be given slowly into the muscle. Avoid injecting into a vein or nerve.

Scientific Evidence:

Fulvestrant, the active ingredient in Faslodex, has shown efficacy in the treatment of hormone receptor-positive breast cancer. Clinical trials have demonstrated that fulvestrant is as effective as aromatase inhibitors in postmenopausal women with advanced breast cancer. Research published in the Journal of Clinical Oncology has highlighted the role of fulvestrant in improving progression-free survival in this patient population.

Additional Information:

It is important to monitor patients for signs of hypersensitivity reactions during Faslodex administration. Common side effects may include injection site reactions, nausea, and fatigue. Patients should be advised to report any unusual symptoms to their healthcare provider promptly.

Pharmacological Effects: Fulvestrant works by binding to the estrogen receptors in breast cancer cells, leading to their degradation and blocking the estrogen signaling pathway. This action inhibits the growth of hormone receptor-positive breast cancer cells.

Comparative Effectiveness: Studies have shown that Faslodex is comparable in efficacy to aromatase inhibitors in the treatment of hormone receptor-positive metastatic breast cancer. Additionally, Faslodex has demonstrated efficacy in patients who have progressed on prior endocrine therapy.